Last updated: February 14, 2026
What is NDC 42571-0128?
This National Drug Code (NDC) refers to Pemibrolizumab (brand name unspecified here), an immune checkpoint inhibitor used primarily in treating certain cancers such as non-small cell lung cancer and melanoma. The drug received FDA approval on June 16, 2022, under the accelerated approval pathway, indicating initial limited data but promising efficacy.
Market Landscape
Indications and Patient Population
- Approved indications include metastatic non-small cell lung cancer (NSCLC), melanoma, and other solid tumors resistant to prior therapies.
- Estimated patient counts are derived from epidemiological data:
- NSCLC in the U.S. affects approximately 250,000 patients annually.
- Melanoma cases approximate 105,000 annually.
- Total eligible population could reach 350,000–400,000 patients nationally, with variable eligibility depending on clinical criteria.
Competitive Positioning
- Market competitors:
- Pembrolizumab (Keytruda): dominant PD-1 inhibitor, $21.4 billion in sales (2022).
- Nivolumab (Opdivo): $9.6 billion in 2022.
- Atezolizumab (Tecentriq): $4.2 billion in 2022.
- NDC 42571-0128 faces competition from these established therapies with proven reimbursement and market penetration.
Regulatory and Reimbursement Factors
- Pricing negotiations are influenced by payer negotiations, value-based agreements, and real-world evidence.
- The drug’s accelerated approval status may lead to enhanced payer scrutiny pending confirmatory trials.
- Outcomes-based agreements are emerging in this space, influencing the final negotiated price.
Market Penetration & Adoption
- First-year sales projections: Targeting 5%–10% of the eligible pool in the U.S.
- Assumed market share: 2%–5% in the first 12 months, rising with clinical data and expanded indications.
- Adoption depends on competitive advantages such as superior efficacy, safety profile, or dosing convenience.
Pricing Dynamics and Projections
Current Pricing Benchmarks
- Benchmark drugs: Pembrolizumab and Nivolumab typically priced at approximately $150,000–$180,000 per year for full treatment courses.
- Initial pricing of NDC 42571-0128 is projected in range:
| Parameter |
Projection |
| Per-Unit Price |
$120,000–$150,000 per year (assuming dosing similar to pembrolizumab) |
| Average Cost per Treatment Course |
$125,000–$150,000 |
| Monthly Cost |
$10,000–$12,500 |
Price Trends
- Premium positioning: If clinical data demonstrates superior efficacy or fewer adverse events, prices could reach $180,000–$200,000 annually.
- Market pressures: As competition intensifies, prices may decline to maintain market share, particularly in off-label use and biosimilar developments.
Growth Projections Over 5 Years
| Year |
Estimated Sales (USD) |
Assumptions |
| 2023 |
$50–$100 million |
Initial adoption, limited indications, conservative market share |
| 2024 |
$200–$400 million |
Expanded indications, increased adoption |
| 2025 |
$500–$800 million |
Broader market penetration, price stabilization |
| 2026 |
$1–$1.5 billion |
Potential label expansions, combination therapies |
| 2027 |
$2 billion+ |
Maturation of reimbursement pathways, global expansion |
Risks & Opportunities
- Risks: Slow uptake due to competition, reimbursement hurdles, or adverse safety profiles.
- Opportunities: Clinical trial success could lead to new indications, expanding market presence. Strategic partnerships may enhance distribution and awareness.
Summary
NDC 42571-0128 is positioned in a competitive, well-established immunotherapy market. Early pricing will likely mirror existing PD-1 inhibitors, with initial annual prices projected between $125,000 and $150,000. Adoption rates depend heavily on clinical efficacy, safety, and payer acceptance. Market growth could reach over $1 billion within five years if the drug captures targeted indications and patient populations.
Key Takeaways
- Launch price: $125,000–$150,000 annually.
- U.S. addressable market: approximately 350,000–400,000 patients.
- Competitive landscape: dominant players with multi-billion dollar sales.
- Growth potential: significant if label expansions or combination strategies succeed.
- Risks include payer reimbursement hurdles and competition from biosimilars or alternative therapies.
FAQs
-
How does the pricing of NDC 42571-0128 compare to existing PD-1 inhibitors?
It will likely be priced within the $125,000–$150,000 range, similar to pembrolizumab and nivolumab, with potential adjustments based on clinical data.
-
What factors influence the drug's market adoption?
Efficacy, safety profile, reimbursement policies, and clinical guideline endorsements.
-
What are the main market risks?
Delayed label expansions, reimbursement challenges, and competition from established therapies or biosimilars.
-
Can the drug’s price increase over time?
Yes, with demonstrated superior efficacy, fewer adverse events, or expanded indications, prices might rise.
-
What is the potential for global market entry?
It depends on regulatory approval timelines, local healthcare policies, and competitive landscape but could significantly increase revenue potential.
Citations
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] FDA, "Accelerated Approval Program," 2022.
[3] EvaluatePharma, "World Market Revenue for PD-1/PD-L1 Inhibitors," 2022.
